Health Care • Biotechnology: In Vitro & In Vivo Diagnostic Substances
$96.65 ▲ +0.68
(+0.71%)
MKT CAP: $6.40B • VOL: 657.3K
52W L $25 52W H $116
ORKA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$122.1M | -$88.1M | -$7.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$105.4M | -$83.7M | -$5.3M |
| EBITDA (Normalized) | -$121.9M | -$88.0M | -$7.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$88.2M | -$57.8M | -$5.0M |
| Capital Expenditures (CapEx) | $209.0K | $189.0K | $0 |
| Free Cash Flow (FCF) | -$88.4M | -$58.0M | -$5.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -22.3% | -21.3% | -0.3% |
| Cash & Short-Term Equivalents | $46.9M | $61.6M | $387.1M |
| Total Debt (Short + Long Term) | $7.5M | $6.2M | $823.6M |
| Total Stockholders' Equity | $471.9M | $382.2M | $1.69B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ORKA.